257 related articles for article (PubMed ID: 35180111)
1. Olfaction, Cognitive Impairment, and PET Biomarkers in Community-Dwelling Older Adults.
Tian Q; Bilgel M; Moghekar AR; Ferrucci L; Resnick SM
J Alzheimers Dis; 2022; 86(3):1275-1285. PubMed ID: 35180111
[TBL] [Abstract][Full Text] [Related]
2. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
3. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
4. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
6. Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment.
Mundada NS; Rojas JC; Vandevrede L; Thijssen EH; Iaccarino L; Okoye OC; Shankar R; Soleimani-Meigooni DN; Lago AL; Miller BL; Teunissen CE; Heuer H; Rosen HJ; Dage JL; Jagust WJ; Rabinovici GD; Boxer AL; La Joie R
Alzheimers Res Ther; 2023 Sep; 15(1):157. PubMed ID: 37740209
[TBL] [Abstract][Full Text] [Related]
7. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
8. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease.
Halawa OA; Gatchel JR; Amariglio RE; Rentz DM; Sperling RA; Johnson KA; Marshall GA;
Alzheimers Res Ther; 2019 Jan; 11(1):14. PubMed ID: 30704519
[TBL] [Abstract][Full Text] [Related]
9. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
Hatashita S; Yamasaki H
PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Binette AP; Vogel JW; Klein G; Borroni E; Tonietto M; Strandberg O; Mattsson-Carlgren N; Palmqvist S; Pontecorvo MJ; Iaccarino L; Stomrud E; Ossenkoppele R; Smith R; Hansson O;
JAMA Neurol; 2023 Jun; 80(6):614-623. PubMed ID: 37155176
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal assessment of amyloid-beta deposition in initially amyloid-negative non-demented individuals with [11C]-PIB PET imaging.
Hatashita S; Wakebe D
Medicine (Baltimore); 2021 Sep; 100(35):e27055. PubMed ID: 34477136
[TBL] [Abstract][Full Text] [Related]
12. The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study.
Ismail R; Parbo P; Madsen LS; Hansen AK; Hansen KV; Schaldemose JL; Kjeldsen PL; Stokholm MG; Gottrup H; Eskildsen SF; Brooks DJ
J Neuroinflammation; 2020 May; 17(1):151. PubMed ID: 32375809
[TBL] [Abstract][Full Text] [Related]
13. Skeletal muscle mitochondrial function predicts cognitive impairment and is associated with biomarkers of Alzheimer's disease and neurodegeneration.
Tian Q; Bilgel M; Walker KA; Moghekar AR; Fishbein KW; Spencer RG; Resnick SM; Ferrucci L
Alzheimers Dement; 2023 Oct; 19(10):4436-4445. PubMed ID: 37530130
[TBL] [Abstract][Full Text] [Related]
14. Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults.
Chen X; Cassady KE; Adams JN; Harrison TM; Baker SL; Jagust WJ
J Neurosci; 2021 Jan; 41(2):366-375. PubMed ID: 33219003
[TBL] [Abstract][Full Text] [Related]
15. Regional Tau Deposition Reflects Different Pathways of Subsequent Neurodegeneration and Memory Decline in Cognitively Normal Older Adults.
Chen X; Toueg TN; Harrison TM; Baker SL; Jagust WJ
Ann Neurol; 2024 Feb; 95(2):249-259. PubMed ID: 37789559
[TBL] [Abstract][Full Text] [Related]
16. Association of Emerging β-Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults.
Farrell ME; Papp KV; Buckley RF; Jacobs HIL; Schultz AP; Properzi MJ; Vannini P; Hanseeuw BJ; Rentz DM; Johnson KA; Sperling RA
Neurology; 2022 Apr; 98(15):e1512-e1524. PubMed ID: 35338074
[TBL] [Abstract][Full Text] [Related]
17. A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer's Disease Continuum.
Coomans EM; Verberk IMW; Ossenkoppele R; Verfaillie SCJ; Visser D; Gouda M; Tuncel H; Wolters EE; Timmers T; Windhorst AD; Golla SSV; Scheltens P; van WM; Flier D; van Berckel BNM; Teunissen CE
J Nucl Med; 2023 Mar; 64(3):437-443. PubMed ID: 36229187
[TBL] [Abstract][Full Text] [Related]
18. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
19. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
[TBL] [Abstract][Full Text] [Related]
20. The relationship of insulin resistance and diabetes to tau PET SUVR in middle-aged to older adults.
Ennis GE; Betthauser TJ; Koscik RL; Chin NA; Christian BT; Asthana S; Johnson SC; Bendlin BB
Alzheimers Res Ther; 2023 Mar; 15(1):55. PubMed ID: 36932429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
